human bub1 Search Results


94
Genecopoeia bub1 promoter reporter clones
Bub1 Promoter Reporter Clones, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bub1/Promoter+reporter+clone+for+Human+BUB1/pm31272759-74-0-4
Average 94 stars, based on 1 article reviews
bub1 promoter reporter clones - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Novus Biologicals bub1
Transcriptomic profiling of CAID patient dermal fibroblasts. ( A ) Volcano plot of the differentially expressed genes at early (p8) and late stage (p14). Log 2 fold change: blue, <-1; red, >1. ( B ) Number of up-regulated and down-regulated genes identified at early (p8) and late passage (p14). ( C ) Cluster of genes associated with cell cycle identified at p8 that became larger at p14. ( D ) mRNA expression of candidate genes at early (p8) and late passage (p14) showing up-regulation of SGO1 , SGO2 , <t>BUB1</t> , PLK1 , ESCO2 , DUSP2 , and BIRC5 and down-regulation of KCND2 , KCNJ2 , and KCNJ8 . Error bars signify SD. For each group, N = 3 independent biological replicates. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). FC, fold change; MUT, K23E; WT, wild-type.
Bub1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bub1/Recombinant+Human+Bub1+GST+(N-Term)+Protein/pmc06369230-388-4-6
Average 90 stars, based on 1 article reviews
bub1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Medema labs human bub1
Transcriptomic profiling of CAID patient dermal fibroblasts. ( A ) Volcano plot of the differentially expressed genes at early (p8) and late stage (p14). Log 2 fold change: blue, <-1; red, >1. ( B ) Number of up-regulated and down-regulated genes identified at early (p8) and late passage (p14). ( C ) Cluster of genes associated with cell cycle identified at p8 that became larger at p14. ( D ) mRNA expression of candidate genes at early (p8) and late passage (p14) showing up-regulation of SGO1 , SGO2 , <t>BUB1</t> , PLK1 , ESCO2 , DUSP2 , and BIRC5 and down-regulation of KCND2 , KCNJ2 , and KCNJ8 . Error bars signify SD. For each group, N = 3 independent biological replicates. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). FC, fold change; MUT, K23E; WT, wild-type.
Human Bub1, supplied by Medema labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bub1/human+bub1/pm36861883-193-11-17
Average 90 stars, based on 1 article reviews
human bub1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sanying Ltd rabbit anti-human bub1 monoclonal antibody
Analysis of <t>BUB1</t> and BUB1B gene differential expression in tumors. ( A ) Analysis of BUB1 gene expression in tumors in TIMER 2.0 database; ( B ) Analysis of BUB1 gene expression analysis in tumors in GEPIA2 database; ( C ) Analysis of BUB1B gene expression analysis in tumors in TIMER 2.0 database; ( D ) Analysis of BUB1B gene expression analysis in tumors in GEPIA2 database. * P < 0.05.
Rabbit Anti Human Bub1 Monoclonal Antibody, supplied by Sanying Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bub1/rabbit+anti+human+bub1+monoclonal+antibody/pmc11269704-60-6-14
Average 90 stars, based on 1 article reviews
rabbit anti-human bub1 monoclonal antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare human bub1 cdna
Analysis of <t>BUB1</t> and BUB1B gene differential expression in tumors. ( A ) Analysis of BUB1 gene expression in tumors in TIMER 2.0 database; ( B ) Analysis of BUB1 gene expression analysis in tumors in GEPIA2 database; ( C ) Analysis of BUB1B gene expression analysis in tumors in TIMER 2.0 database; ( D ) Analysis of BUB1B gene expression analysis in tumors in GEPIA2 database. * P < 0.05.
Human Bub1 Cdna, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bub1/human+bub1+cdna/pm15818396-76-12-5
Average 90 stars, based on 1 article reviews
human bub1 cdna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

N/A
Recombinant protein of human budding uninhibited by benzimidazoles 1 homolog yeast BUB1
  Buy from Supplier

N/A
3 UTR clone of budding uninhibited by benzimidazoles 1 homolog yeast BUB1 for miRNA target validation
  Buy from Supplier

N/A
BUB1 CRISPRa kit CRISPR gene activation of human BUB1 mitotic checkpoint serine threonine kinase
  Buy from Supplier

N/A
BUB1 Rabbit anti-Human Polyclonal (N-Terminus) (Unconjugated) Antibody, (50 µg)
  Buy from Supplier

N/A
Full length Clone DNA of Human BUB1 budding uninhibited by benzimidazoles 1 homolog with C terminal HA tag.
  Buy from Supplier

N/A
Full length Clone DNA of Human BUB1 budding uninhibited by benzimidazoles 1 homolog with N terminal Flag tag.
  Buy from Supplier

N/A
BUB1 Myc DDK tagged Human budding uninhibited by benzimidazoles 1 homolog yeast BUB1
  Buy from Supplier

Image Search Results


Transcriptomic profiling of CAID patient dermal fibroblasts. ( A ) Volcano plot of the differentially expressed genes at early (p8) and late stage (p14). Log 2 fold change: blue, <-1; red, >1. ( B ) Number of up-regulated and down-regulated genes identified at early (p8) and late passage (p14). ( C ) Cluster of genes associated with cell cycle identified at p8 that became larger at p14. ( D ) mRNA expression of candidate genes at early (p8) and late passage (p14) showing up-regulation of SGO1 , SGO2 , BUB1 , PLK1 , ESCO2 , DUSP2 , and BIRC5 and down-regulation of KCND2 , KCNJ2 , and KCNJ8 . Error bars signify SD. For each group, N = 3 independent biological replicates. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). FC, fold change; MUT, K23E; WT, wild-type.

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics

doi: 10.1016/j.jcmgh.2018.10.011

Figure Lengend Snippet: Transcriptomic profiling of CAID patient dermal fibroblasts. ( A ) Volcano plot of the differentially expressed genes at early (p8) and late stage (p14). Log 2 fold change: blue, <-1; red, >1. ( B ) Number of up-regulated and down-regulated genes identified at early (p8) and late passage (p14). ( C ) Cluster of genes associated with cell cycle identified at p8 that became larger at p14. ( D ) mRNA expression of candidate genes at early (p8) and late passage (p14) showing up-regulation of SGO1 , SGO2 , BUB1 , PLK1 , ESCO2 , DUSP2 , and BIRC5 and down-regulation of KCND2 , KCNJ2 , and KCNJ8 . Error bars signify SD. For each group, N = 3 independent biological replicates. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). FC, fold change; MUT, K23E; WT, wild-type.

Article Snippet: Five times excess of BUB1 (H00000699-Q01; Novus Biologicals, Littleton, CO), and TAGLN (NBP1-45267; Novus Biologicals) human recombinant peptides was added to the primary antibody by weight.

Techniques: Expressing

Candidates validation and expression profile of cohesinopathies genes. ( A ) Reverse transcription quantitative PCR (qPCR) validations of SGO1, SGO2, BUB1, PLK1, DUSP2, and KCND2 expression at early (p8) and late (p14) passage. Error bars signify SD. For each condition, the experiment was performed on N = 3 independent biological replicates in technical replicates. Significance was calculated using 1-way analysis of variance with the Bonferroni post-test ( • P < .1, * P < .05, and ** P < .01). ( B ) mRNA expression levels of genes involved in cohesinopathies at early (p8) and late (p14) passage. AFF4, CHOPS syndrome; DDX11, Warsaw breakage syndrome; NIPBL, RAD21, and SMC3, Cornelia de Lange syndrome. Error bars signify SD. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). For each group, N = 3 independent biological replicates. MUT, K23E; WT, wild-type.

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics

doi: 10.1016/j.jcmgh.2018.10.011

Figure Lengend Snippet: Candidates validation and expression profile of cohesinopathies genes. ( A ) Reverse transcription quantitative PCR (qPCR) validations of SGO1, SGO2, BUB1, PLK1, DUSP2, and KCND2 expression at early (p8) and late (p14) passage. Error bars signify SD. For each condition, the experiment was performed on N = 3 independent biological replicates in technical replicates. Significance was calculated using 1-way analysis of variance with the Bonferroni post-test ( • P < .1, * P < .05, and ** P < .01). ( B ) mRNA expression levels of genes involved in cohesinopathies at early (p8) and late (p14) passage. AFF4, CHOPS syndrome; DDX11, Warsaw breakage syndrome; NIPBL, RAD21, and SMC3, Cornelia de Lange syndrome. Error bars signify SD. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). For each group, N = 3 independent biological replicates. MUT, K23E; WT, wild-type.

Article Snippet: Five times excess of BUB1 (H00000699-Q01; Novus Biologicals, Littleton, CO), and TAGLN (NBP1-45267; Novus Biologicals) human recombinant peptides was added to the primary antibody by weight.

Techniques: Biomarker Discovery, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction

Proteomic profiling of CAID patient dermal fibroblasts . ( A ) Venn diagram of proteins differentially expressed in CAID patient/control duos at early (p10) and late passage (p14). ( B ) Protein network of differentially expressed proteins in CAID patients at early (p10) and late (p14) passage. N = 3 independent biological replicates were analyzed for each condition. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). ( C ) Western blot validation of TPM1, TAGLN, and BUB1 overexpression. ( D ) Densitometric quantification of BUB1, TAGLN, and TPM1 overexpression by Western blot. Error bars signify SD. For each group, N = 3 independent biological replicates (2 independent experiments). Significance was calculated by 1-way analysis of variance with the Bonferroni post-test (* P < .05, ** P < .01). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MUT, K23E; WT, wild-type.

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics

doi: 10.1016/j.jcmgh.2018.10.011

Figure Lengend Snippet: Proteomic profiling of CAID patient dermal fibroblasts . ( A ) Venn diagram of proteins differentially expressed in CAID patient/control duos at early (p10) and late passage (p14). ( B ) Protein network of differentially expressed proteins in CAID patients at early (p10) and late (p14) passage. N = 3 independent biological replicates were analyzed for each condition. P values were corrected for multiple testing using the Benjamini–Hochberg method (q value). ( C ) Western blot validation of TPM1, TAGLN, and BUB1 overexpression. ( D ) Densitometric quantification of BUB1, TAGLN, and TPM1 overexpression by Western blot. Error bars signify SD. For each group, N = 3 independent biological replicates (2 independent experiments). Significance was calculated by 1-way analysis of variance with the Bonferroni post-test (* P < .05, ** P < .01). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MUT, K23E; WT, wild-type.

Article Snippet: Five times excess of BUB1 (H00000699-Q01; Novus Biologicals, Littleton, CO), and TAGLN (NBP1-45267; Novus Biologicals) human recombinant peptides was added to the primary antibody by weight.

Techniques: Control, Western Blot, Biomarker Discovery, Over Expression

Gastrointestinal histology of CAID patients. Biopsy specimens (5 μm) from controls and individuals with CAID. All biopsy specimens are oriented to show the villi on top and the muscularis externa at the bottom. ( A ) Negative controls show that no signal was obtained in the absence of the primary antibody. ( B–D ) DAB staining was performed for SGO1, BUB1, and TAGLN. ( B ) SGO1 and ( C ) BUB1 show higher expression in the villi and muscularis externa of CAID patient intestines vs controls. ( D ) TAGLN shows higher expression in muscularis mucosa and muscularis externa in CAID patient intestines vs controls (N = 3, 2 shown). Experiment was performed 3 times independently on 3 biological replicates for each condition. The Scale bar is 1000 μm except MUT/MUT1 SGO1, BUB1, TAGLN, and MUT/MUT 2 TAGLN where Scale bar : 2000 μm. Images were acquired using a Zeiss AxioScan Z1 slide scanner and processed with Zen software. MUT, K23E; WT, wild-type.

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics

doi: 10.1016/j.jcmgh.2018.10.011

Figure Lengend Snippet: Gastrointestinal histology of CAID patients. Biopsy specimens (5 μm) from controls and individuals with CAID. All biopsy specimens are oriented to show the villi on top and the muscularis externa at the bottom. ( A ) Negative controls show that no signal was obtained in the absence of the primary antibody. ( B–D ) DAB staining was performed for SGO1, BUB1, and TAGLN. ( B ) SGO1 and ( C ) BUB1 show higher expression in the villi and muscularis externa of CAID patient intestines vs controls. ( D ) TAGLN shows higher expression in muscularis mucosa and muscularis externa in CAID patient intestines vs controls (N = 3, 2 shown). Experiment was performed 3 times independently on 3 biological replicates for each condition. The Scale bar is 1000 μm except MUT/MUT1 SGO1, BUB1, TAGLN, and MUT/MUT 2 TAGLN where Scale bar : 2000 μm. Images were acquired using a Zeiss AxioScan Z1 slide scanner and processed with Zen software. MUT, K23E; WT, wild-type.

Article Snippet: Five times excess of BUB1 (H00000699-Q01; Novus Biologicals, Littleton, CO), and TAGLN (NBP1-45267; Novus Biologicals) human recombinant peptides was added to the primary antibody by weight.

Techniques: Staining, Expressing, Software

Gastrointestinal fluorescent histology of CAID patients . Biopsy specimens (5 μm) from controls and individuals with CAID. All biopsy specimens are oriented to show the villi on top and the muscularis externa at the bottom. ( A ) Immunizing peptide blocking experiment showing the specificity of BUB1 and TAGLN antibodies. ( B ) Negative controls showing that no signal was obtained in the villi (SGO1 and BUB1), the muscularis mucosa (TAGLN), and the muscularis externa (SGO1, BUB1, and TAGLN) in the absence of the primary antibody. ( C and D ) Fluorescence staining was performed for SGO1, BUB1, and TAGLN. ( C ) SGO1 and BUB1 expression were higher in the villi and muscularis externa of CAID patient intestines vs controls. In controls, SGO1 expression was mainly nuclear whereas in CAID patients, SGO1 was delocalized to the cytoplasm. ( D ) TAGLN expression was higher in the muscularis mucosa and the muscularis externa in CAID patient intestines vs controls. V, villi; ME, muscularis externa; MM, muscularis mucosa (N = 3, 2 shown). Experiment was performed 3 times independently on 3 biological replicates for each condition. Scale bar : 100 μm. Images were acquired at 40× using a Leica DMi8 inverted fluorescence microscope and processed with Leica LAS X software. DAPI, 4′,6-diamidino-2-phenylindole. MUT, K23E; WT, wild-type.

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics

doi: 10.1016/j.jcmgh.2018.10.011

Figure Lengend Snippet: Gastrointestinal fluorescent histology of CAID patients . Biopsy specimens (5 μm) from controls and individuals with CAID. All biopsy specimens are oriented to show the villi on top and the muscularis externa at the bottom. ( A ) Immunizing peptide blocking experiment showing the specificity of BUB1 and TAGLN antibodies. ( B ) Negative controls showing that no signal was obtained in the villi (SGO1 and BUB1), the muscularis mucosa (TAGLN), and the muscularis externa (SGO1, BUB1, and TAGLN) in the absence of the primary antibody. ( C and D ) Fluorescence staining was performed for SGO1, BUB1, and TAGLN. ( C ) SGO1 and BUB1 expression were higher in the villi and muscularis externa of CAID patient intestines vs controls. In controls, SGO1 expression was mainly nuclear whereas in CAID patients, SGO1 was delocalized to the cytoplasm. ( D ) TAGLN expression was higher in the muscularis mucosa and the muscularis externa in CAID patient intestines vs controls. V, villi; ME, muscularis externa; MM, muscularis mucosa (N = 3, 2 shown). Experiment was performed 3 times independently on 3 biological replicates for each condition. Scale bar : 100 μm. Images were acquired at 40× using a Leica DMi8 inverted fluorescence microscope and processed with Leica LAS X software. DAPI, 4′,6-diamidino-2-phenylindole. MUT, K23E; WT, wild-type.

Article Snippet: Five times excess of BUB1 (H00000699-Q01; Novus Biologicals, Littleton, CO), and TAGLN (NBP1-45267; Novus Biologicals) human recombinant peptides was added to the primary antibody by weight.

Techniques: Blocking Assay, Fluorescence, Staining, Expressing, Microscopy, Software

Primers List for Reverse-Transcription PCR Validations

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics

doi: 10.1016/j.jcmgh.2018.10.011

Figure Lengend Snippet: Primers List for Reverse-Transcription PCR Validations

Article Snippet: Five times excess of BUB1 (H00000699-Q01; Novus Biologicals, Littleton, CO), and TAGLN (NBP1-45267; Novus Biologicals) human recombinant peptides was added to the primary antibody by weight.

Techniques: Reverse Transcription, Sequencing

Analysis of BUB1 and BUB1B gene differential expression in tumors. ( A ) Analysis of BUB1 gene expression in tumors in TIMER 2.0 database; ( B ) Analysis of BUB1 gene expression analysis in tumors in GEPIA2 database; ( C ) Analysis of BUB1B gene expression analysis in tumors in TIMER 2.0 database; ( D ) Analysis of BUB1B gene expression analysis in tumors in GEPIA2 database. * P < 0.05.

Journal: Scientific Reports

Article Title: Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

doi: 10.1038/s41598-024-67528-2

Figure Lengend Snippet: Analysis of BUB1 and BUB1B gene differential expression in tumors. ( A ) Analysis of BUB1 gene expression in tumors in TIMER 2.0 database; ( B ) Analysis of BUB1 gene expression analysis in tumors in GEPIA2 database; ( C ) Analysis of BUB1B gene expression analysis in tumors in TIMER 2.0 database; ( D ) Analysis of BUB1B gene expression analysis in tumors in GEPIA2 database. * P < 0.05.

Article Snippet: Samples were incubated with primary antibody (rabbit anti-human BUB1 and BUBIB monoclonal antibody, 1:200) (Sanying Biotechnology Co. Ltd., Wuhan, Hubei, China), followed by incubation with secondary antibody (HRP-labeled goat anti-rabbit II antibody, 1:200) (Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China).

Techniques: Quantitative Proteomics, Gene Expression

BUB1 and BUB1B expression in EC. ( A ) BUB1 expression in normal endometrium and EC (XianTao database); ( B ) BUB1 expression in normal endometrium and EC (IHC); ( C ) BUB1B expression in normal endometrium and EC (XiaoTao database); ( D ) BUB1B expression in normal endometrium and EC (IHC); ( E ) BUB1 ROC curve in EC; ( F ) BUB1B ROC curve in EC.

Journal: Scientific Reports

Article Title: Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

doi: 10.1038/s41598-024-67528-2

Figure Lengend Snippet: BUB1 and BUB1B expression in EC. ( A ) BUB1 expression in normal endometrium and EC (XianTao database); ( B ) BUB1 expression in normal endometrium and EC (IHC); ( C ) BUB1B expression in normal endometrium and EC (XiaoTao database); ( D ) BUB1B expression in normal endometrium and EC (IHC); ( E ) BUB1 ROC curve in EC; ( F ) BUB1B ROC curve in EC.

Article Snippet: Samples were incubated with primary antibody (rabbit anti-human BUB1 and BUBIB monoclonal antibody, 1:200) (Sanying Biotechnology Co. Ltd., Wuhan, Hubei, China), followed by incubation with secondary antibody (HRP-labeled goat anti-rabbit II antibody, 1:200) (Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China).

Techniques: Expressing

BUB1 and BUB1B gene variations in EC. ( A ) BUB1 gene alteration in EC; ( B ) BUB1 gene alteration in relation to OS in EC; ( C ) BUB1 gene alteration in relation to PFS in EC. ( D ) BUB1B gene alteration in EC; € BUB1B gene alteration in relation to OS in EC; F. BUB1B gene alteration in relation to PFS in EC.

Journal: Scientific Reports

Article Title: Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

doi: 10.1038/s41598-024-67528-2

Figure Lengend Snippet: BUB1 and BUB1B gene variations in EC. ( A ) BUB1 gene alteration in EC; ( B ) BUB1 gene alteration in relation to OS in EC; ( C ) BUB1 gene alteration in relation to PFS in EC. ( D ) BUB1B gene alteration in EC; € BUB1B gene alteration in relation to OS in EC; F. BUB1B gene alteration in relation to PFS in EC.

Article Snippet: Samples were incubated with primary antibody (rabbit anti-human BUB1 and BUBIB monoclonal antibody, 1:200) (Sanying Biotechnology Co. Ltd., Wuhan, Hubei, China), followed by incubation with secondary antibody (HRP-labeled goat anti-rabbit II antibody, 1:200) (Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China).

Techniques:

BUB1 or BUB1B and EC immune filtration. ( A ) BUB1 expression was associated with TIL abundance in EC; ( B ) BUB1 expression was associated with immunosuppressants in EC; ( C ) BUB1 expression and immunostimulants in EC. ( D ) BUB1B expression was associated with TIL abundance in EC; E. BUB1B expression was associated with immunosuppressants in EC; ( F ) BUB1B expression and immunostimulants in EC.

Journal: Scientific Reports

Article Title: Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

doi: 10.1038/s41598-024-67528-2

Figure Lengend Snippet: BUB1 or BUB1B and EC immune filtration. ( A ) BUB1 expression was associated with TIL abundance in EC; ( B ) BUB1 expression was associated with immunosuppressants in EC; ( C ) BUB1 expression and immunostimulants in EC. ( D ) BUB1B expression was associated with TIL abundance in EC; E. BUB1B expression was associated with immunosuppressants in EC; ( F ) BUB1B expression and immunostimulants in EC.

Article Snippet: Samples were incubated with primary antibody (rabbit anti-human BUB1 and BUBIB monoclonal antibody, 1:200) (Sanying Biotechnology Co. Ltd., Wuhan, Hubei, China), followed by incubation with secondary antibody (HRP-labeled goat anti-rabbit II antibody, 1:200) (Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China).

Techniques: Filtration, Expressing

The relation between  BUB1  and BUB1B expression with clinicopathological characteristics in EC.

Journal: Scientific Reports

Article Title: Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

doi: 10.1038/s41598-024-67528-2

Figure Lengend Snippet: The relation between BUB1 and BUB1B expression with clinicopathological characteristics in EC.

Article Snippet: Samples were incubated with primary antibody (rabbit anti-human BUB1 and BUBIB monoclonal antibody, 1:200) (Sanying Biotechnology Co. Ltd., Wuhan, Hubei, China), followed by incubation with secondary antibody (HRP-labeled goat anti-rabbit II antibody, 1:200) (Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China).

Techniques: Expressing

Influence of BUB1 and BUBIB knockdown on EC cell phenotype. ( A ) The growth of Ishikawa cells in each group; ( B ) The migration rates of Ishikawa cells in each group: blank group (50.99 ± 1.02)%, NC-siRNA group (66.50 ± 7.74)%, BUB1-siRNA group (34.87 ± 4.26)%, and BUB1B-siRNA group (31.96 ± 4.72)%; ( C ) The number of cells that crossed the membrane in each group: blank group (127.3 ± 4.8), NC-siRNA group (125.3 ± 3.9), BUB1-siRNA group (48.6 ± 3.2), and BUB1B-siRNA group (35.0 ± 2.1). * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Scientific Reports

Article Title: Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

doi: 10.1038/s41598-024-67528-2

Figure Lengend Snippet: Influence of BUB1 and BUBIB knockdown on EC cell phenotype. ( A ) The growth of Ishikawa cells in each group; ( B ) The migration rates of Ishikawa cells in each group: blank group (50.99 ± 1.02)%, NC-siRNA group (66.50 ± 7.74)%, BUB1-siRNA group (34.87 ± 4.26)%, and BUB1B-siRNA group (31.96 ± 4.72)%; ( C ) The number of cells that crossed the membrane in each group: blank group (127.3 ± 4.8), NC-siRNA group (125.3 ± 3.9), BUB1-siRNA group (48.6 ± 3.2), and BUB1B-siRNA group (35.0 ± 2.1). * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Samples were incubated with primary antibody (rabbit anti-human BUB1 and BUBIB monoclonal antibody, 1:200) (Sanying Biotechnology Co. Ltd., Wuhan, Hubei, China), followed by incubation with secondary antibody (HRP-labeled goat anti-rabbit II antibody, 1:200) (Zhongshan Jinqiao Biotechnology Co. Ltd., Beijing, China).

Techniques: Knockdown, Migration, Membrane